ASX:KZA NASDAQ:KZIA

Kazia Therapeutics Ltd

Market:

ASX

Market Cap:

$37.3 m

Price

0.60 AUD

Change

-5.51%

52 weeks high

0.80

52 weeks low

0.32

00.54

Director Interviews

In brief

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Kazia Therapeutics to share pipeline results with market and clinicians

Kazia Therapeutics Ltd - Kazia Therapeutics shares pipeline results with market and clinicians

Snapshot

A young biotech with brain cancer and ovarian cancer therapeutics in its pipeline.
The company's early-stage research with initial results from a brain cancer trial are expected in December quarter.
Its pipeline offers hope to patients and clinicians in difficult to treat cancers.

Interviews

Kazia Therapeutics Ltd - Kazia Therapeutics releases data from study of GDC-0084 into aggressive form of brain cancer

Health Full interview: Kazia Therapeutics releases data from study of GDC-0084 into aggressive form of brain cancer

on 24/11/19

Kazia Therapeutics Ltd - Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Health Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

on 30/9/19

Health Kazia Therapeutics releases new safety data to assist in brain cancer treatments

on 7/5/19

Health Kazia Therapeutics to present positive ovarian cancer drug data at AACR annual meeting

on 1/4/19